Cipla Launches HUENA®, India’s First Non-Antibiotic UTI Drug Kumar Jeetendra | September 8, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for Cipla in the fight against Anti-Microbial Resistance (AMR) and reinforces its commitment …
Revolutionizing Diagnostics: How AST is Transforming Clinical Microbiology Kumar Jeetendra | March 18, 2026 The ability to give quick and accurate diagnoses is of paramount importance to the specialized fields of the ever-evolving world of healthcare. One of the most state-of-the-art innovations in healthcare and clinical microbiology laboratories is Antimicrobial Susceptibility Testing (AST), the newest technology for helping clinicians with the choice of treatment for an infectious disease. Providing …
